Search research articles
Contact Us
Filters
Showing results (781-790 of 839) with videos related to
Page
of 84
Sort By:
The New England Journal of Medicine
|
June 2, 2025
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
Patrick M Forde, Jonathan D Spicer, Mariano Provencio, et al.
JAMA Oncology
|
November 29, 2016
Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)
Paul W Sperduto, T Jonathan Yang, Kathryn Beal, et al.
Nature Communications
|
July 15, 2026
Uncovering an alternate pathway of antibiotic resistance in spore-forming bacteria
Yogitha N Srikhanta, Clara E Bate, Desirel Ng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2017
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
Lars D Engstrom, Ruth Aranda, Matthew Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2019
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
Neal Ready, Matthew D Hellmann, Mark M Awad, et al.
Cell Reports. Medicine
|
August 2, 2024
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF<sup>V600E</sup> lung adenocarcinoma
Marie-Julie Nokin, Elodie Darbo, Elodie Richard, et al.
Cancer Immunology Research
|
November 19, 2016
Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
Mark M Awad, Robert E Jones, Hongye Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2025
First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC
Federica Pecci, Hui Li, Alessandro Di Federico, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2020
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50
J F Gainor, H Rizvi, E Jimenez Aguilar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 12, 2023
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC
Joao V Alessi, Arielle Elkrief, Biagio Ricciuti, et al.
Page
of 84
Search research articles
Search
Showing results (781-790 of 839) with videos related to
Sort By:
Page
of 84
The New England Journal of Medicine
|
June 2, 2025
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
Patrick M Forde, Jonathan D Spicer, Mariano Provencio, et al.
JAMA Oncology
|
November 29, 2016
Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)
Paul W Sperduto, T Jonathan Yang, Kathryn Beal, et al.
Nature Communications
|
July 15, 2026
Uncovering an alternate pathway of antibiotic resistance in spore-forming bacteria
Yogitha N Srikhanta, Clara E Bate, Desirel Ng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2017
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
Lars D Engstrom, Ruth Aranda, Matthew Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2019
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
Neal Ready, Matthew D Hellmann, Mark M Awad, et al.
Cell Reports. Medicine
|
August 2, 2024
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF<sup>V600E</sup> lung adenocarcinoma
Marie-Julie Nokin, Elodie Darbo, Elodie Richard, et al.
Cancer Immunology Research
|
November 19, 2016
Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
Mark M Awad, Robert E Jones, Hongye Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2025
First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC
Federica Pecci, Hui Li, Alessandro Di Federico, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2020
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50
J F Gainor, H Rizvi, E Jimenez Aguilar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 12, 2023
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC
Joao V Alessi, Arielle Elkrief, Biagio Ricciuti, et al.
Page
of 84